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Abstract. Neuropeptide precursors are traditionally 
viewed as molecules destined to be cleaved into bioac- 
tive peptides, which are then released from the cell to 
act on target cell surface receptors. In this report we 
demonstrate nuclear localization of the enkephalin pre- 
cursor, proenkephalin, in rodent and human embryonic 
fibroblasts (Swiss 3T3 and MRC-5 cells) and in rodent 
myoblasts (C2C12 cells). Nuclear proenkephalin, de- 
tected by immunofluorescence with a panel of anti- 
proenkephalin monoclonal antibodies, is distributed 
predominantly in three patterns. Selective abolition of 
these patterns with salt, nuclease, or methanol is associ- 
ated with liberation of immunoprecipitable proen- 
kephalin into the extraction supernatant. Proenkepha- 
lin antigenic domains, mapped using phage display 
libraries and synthetic peptides, are differentially  re- 
vealed in the three distribution patterns. Selective 
epitope revelation may reflect different conformational 
forms of proenkephalin or its existence in complexes 
with other nuclear proteins, forms which therefore have 
different biochemical associations with the nuclear sub- 
structure. In fibroblast cell populations in transition to 
growth arrest, nuclear proenkephalin responds 
promptly to mitogen withdrawal and cell-cell contact 
by transient, virtually synchronous unmasking of multi- 
ple antigenic domains in a fine punctate distribution. A 
similar phenomenon is observed in myoblasts undergo- 
ing differentiation. The acknowledgment of growth ar- 
rest and differentiation signals by nuclear proenkepha- 
lin suggests its integration with transduction pathways 
mediating these signals. 
To begin to address the mechanism of nuclear target- 
ing, we have transfected mutated and nonmutated 
proenkephalin into COS (African green monkey kid- 
ney) cells. Nonmutated proenkephalin is localized ex- 
clusively in the cytoplasm; however, proenkephalin mu- 
tated at the first ATG codon, or devoid of its signal 
peptide sequence, is targeted to the nucleus as well as 
to the cytoplasm. From this we speculate that nuclear 
proenkephalin arises from a primary translation prod- 
uct that lacks a signal peptide sequence because of initi- 
ation at a different site. 
p 
ROENKEPHALIN, the precursor to the opioid penta- 
peptides Met- and Leu-enkephalin (Hughes et al., 
1975), is substantially conserved from Xenopus to 
humans (Comb et al., 1982; Martens and Herbert, 1984). 
There  is  accumulating evidence for the involvement of 
proenkephalin and its derivatives  in cellular  growth con- 
trol and differentiation. The proenkephalin gene is tran- 
siently expressed in the developing central nervous system 
and in nonneural tissues of mesodermal origin (Keshet et 
al., 1989). Proenkephalin mRNA is present at a high level 
in proliferating neuroepithelioma cells (Verbeeck et al., 
1990)  and  primary  chondrocyte  cultures  (Villiger  and 
Lotz, 1992); differentiation is accompanied by downregu- 
lation of proenkephalin expression.  There is substantial 
upregulation of proenkephalin gene transcription upon ac- 
Address all  correspondence to Dr.  Barbara A.  Spruce,  Department of 
Anatomy  and  Physiology,  Medical  Sciences  Institute,  University  of 
Dundee, Dundee DD1 4HN, United Kingdom. Tel.: 44-1382-344751. Fax: 
44-1382-344213. 
tivation of T helper cells (Zurawski et al., 1986). Opioid in- 
hibition of neural cell proliferation (Hauser, 1992) and dif- 
ferentiation  (Hauser  et  al.,  1989) has  been  described. 
Enkephalin precursor protein exists at significant levels in 
cell types such as astroglia  (Melner et al., 1990; Spruce et 
al., 1990) and lymphocytes (Roth et al., 1989), which sug- 
gests a role for proenkephalin itself. 
Proenkephalin has to date only been described to exist 
in the cytoplasm, usually in a secretory pathway distribu- 
tion. Cells that release unprocessed proenkephalin, such 
as astrocytes (Batter et al., 1991), also release processing 
enzymes (Vilijn et al., 1989), which suggests that extracel- 
lular cleavage  of proenkephalin may occur.  Even if cell 
surface signaling is occurring via small processed peptides, 
biological activity may still be regulated through the intact 
precursor.  Delta-like opioid receptors and novel, possibly 
chromatin-associated, opioid binding sites  have recently 
been  localized  to  the  nucleus  of  neuroblastoma  cells 
(Belcheva  et al., 1993), raising  the possibility  of nuclear 
sites of opioid action. 
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kephalin within the nucleus of fibroblast and myoblast cell 
lines.  Antigenic domains on the proenkephalin molecule 
are differentially responsive to changes in growth or dif- 
ferentiation state of the cell population. We also show that 
transfected proenkephalin in which the normal ATG initi- 
ation codon has been mutated, or from which  the signal 
peptide  has  been  deleted,  is  targeted  to  the  nucleus  of 
COS cells.  Our ultimate  question is why a  neuropeptide 
precursor, generally viewed as a secretory molecule, has a 
dual fate as a nuclear protein closely integrated with exter- 
nal signals that mediate changes in growth state, the an- 
swer to which may have its basis in evolution. 
Materials and Methods 
Immunolocalization 
Cells were seeded at densities between 0.5 and 104 per cm  2 (0.2 x  105 per 
cm  2 for  contact  inhibition  experiments)  either  into  plastic  slide  flasks 
(Nunc,  Roskilde,  Denmark) or onto polylysine-coated glass coverslips, 
then  fixed  and  stained  after  24  h  or  longer.  Cells  were  fixed  in  4% 
paraformaldehyde (30 min minimum), blocked, and permeabilized in 10% 
FCS, 0.2% Tween in PBS; antibody incubations (2 h to overnight) were 
carried out in blocking buffer; wash steps were in 1% BSA, 0.2% Tween 
in PBS. Indirect immunofluorescence detection was used (fluorochrome- 
conjugated second antibodies from Jackson Immunoresearch Laborato- 
ries, Avondale, PA). DNA was visualized with propidium iodide at 1 ~g/ 
ml in mounting medium. All microscopy was performed with a  Biorad/ 
MRC Lasersharp confocal microscope (Bio-Rad, U.K.). 
Nuclear Isolation and Immunoblotting 
Subconfluent cells were scraped into cold nuclear isolation buffer (NIB; 
10 mM Tris-HC1, pH 7.6, 10 mM NaC1, 3 mM MgCl2, 0.5% NP40 plus pro- 
tease inhibitors:  1 mM benzamidine, 1  ixg/ml leupeptin, pepstatin,  and 
aprotinin).  Nuclei were  released from cells by homogenization using a 
tight-fitting pestle in a glass-glass homogenizer, then centrifuged through 
a cushion of 30% sucrose in NIB at 1,000 g for 10 min. The isolated nuclei 
were resuspended in 10 mM Tris-HCl, pH 7.6, 0.5 M NaCl, sonicated for 1 
min, then  added  to  an  equal  volume of twofold  concentrated  sample 
buffer before  electrophoresis on  a  12%  denaturing polyacrylamide gel. 
Proteins were electroblotted  onto nitrocellulose; blocking and antibody 
incubations were carried out in 5% powdered milk, 0.2% Tween in PBS. 
A  chemiluminescence detection system (ECL; Amersham International, 
Amersham, UK) was used. 
Nuclear Extraction 
Pelleted cells were preextracted in cold CSK buffer (10 mM PIPES, pH 
6.8,  100 mM NaCl, 300 mM sucrose, 3 mM MgC12, 1 mM EGTA, 0.5% 
Triton) plus RNAsin and protease inhibitors (1 mM benzamidine, 1 mM 
PMSF, 1 txg/ml aprotinin, pepstatin A, and leupeptin) for 3 min and then 
centrifuged at 650 g for 5 min. Pellets were then extracted with either salt 
or nuclease. Salt extraction was carried out with 0.25 M  ammonium sul- 
fate, pH 6.8,  in CSK buffer without NaC1 plus protease inhibitors at 4°C 
for 5 min. Nuclease extraction was carried out with DNAse 1 at 50 Ixg/ml 
in low salt (50 mM NaC1) CSK buffer plus protease inhibtors for 20 min at 
25°C, followed by RNAse to a final concentration of 25 tJ.gtml for 10 min 
at 25°C. In each case, postextraction pellets (650-1,000 g for 5 min) were 
subjected to immunoblot and supernatants to immunoprecipitation. 
Immunoprecipitation 
1 ixl of monoclonal antibody ascites fluid was added to 250 Ixl of extraction 
supernatant and incubated on ice  for  1 h. 20 ixl of Protein  G-coupled 
Sepharose beads (Sigma Chemical Co., St. Louis, MO) at 2 mg/ml in CSK 
buffer was added, followed by an additional 1 h of incubation. Protein 
G-Sepharose pellets were washed four times in cold CSK buffer, added to 
an equal volume of twolold  concentrated, boiling, SDS  sample buffer, 
then boiled for 5 rain. Samples were clarified by centrifugation, then sub- 
jected  to  denaturing  PAGE  followed  by  electroblotting.  Blots  were 
probed with a different PE mAb from the precipitating antibody and the 
immunoprecipitation products  revealed  using ECL  chemiluminescence 
detection. 
Mutagenesis  and Transient Transfections 
into COS Cells 
Nonmutated human proenkephalin cDNA incorporating the entire cod- 
ing region and the two in-frame upstream CTG codons was isolated by 
PCR from the vector phPE-9 (Comb et aL, 1982) using primers that con- 
tained BamHI restriction enzyme cleavage sites to facilitate subcloning: 
upstream primer (STA3), CTCGGATCCGTGTCTGAACCCGGCqq~- 
TCC; downstream primer (STOP1), CTCGGATCCTTAAAATCTCAT- 
AAATCCTCC. Proenkephalin mutated to remove the signal peptide se- 
quence  (ATGAsig)  was  isolated  by  PCR  using  an  upstream  primer 
(STA4)  that  would  bind  to  the  proenkephalin  sequence immediately 
downstream from the signal sequence and that contained a BamHI restric- 
tion enzyme site and an ATG initiation codon:  STA4, CTCGGATCC- 
ATGGAATGCAGCCAGGA'ITGCGCG; STOP1 was again used as the 
downstream primer. Site-directed mutagenesis (Transformer Mutagenesis 
Kit; Clontech, Palo Alto,  CA) was used to  change the upstream CTG 
codons to TTG and the first ATG codon to ATC, from which translation 
could not be initiated. Error-free mutagenesis was confirmed by DNA se- 
quencing. 
Wild-type and mutant proenkephalin cDNAs were subcloned into the 
BamH1 site of the vector pcDNA3 (Invitrogen, San Diego, CA). pcDNA3: 
PE constructs were cotransfected into COS cells with pSV[3gal  (Promega 
Corp., Madison, WI) by electroporation using a  gene pulser (Bio-Rad). 
Before electroporation, COS cells were grown in 14-cm dishes in DME 
plus 10% FCS to a density of 3-4 ×  106 cells per dish. For electroporation 
they were trypsinised, washed twice in serum-free DME without antibiot- 
ics, resuspended in 0.8 ml ice-cold DME, then transferred to chilled elec- 
troporation chambers. 10 Ixg pcDNA3:PE and 10 p~g pSVI3gal  as circular 
plasmid DNAs were added to each chamber, and the cells and DNA were 
incubated on ice for 10 min. Control cells were incubated with pSVI3gal 
alone. Electroporation was carried out at 0.25 kV at a capacitance of 500 
microfarads. Cells were  returned to  ice for  an additional  10 min, then 
plated  at  5  ×  104 cells per milliliter onto polylysine-coated coverslips. 
Cells were fixed with 4%  paraformaldehyde and stained in parallel  for 
proenkephalin and 13-galactosidase  expression 52 to 65 h later. 13-galactosi- 
dase expression was assessed by incubating fixed cells with 0.25  mg/ml 
X-gal in PBS containing 5 mM potassium ferricyanide, 5 mM potassium 
ferrocyanide, and 2 mM magnesium  chloride at 37°C for 8 h. Proenkepha- 
lin immunostaining  was performed as described previously. 
Results 
Subnuclear Localization  of Proenkephalin 
in Multiple Domains 
Using a panel of 15 monoclonal antibodies (PE mAbs; PE-1, 
2, 13-25) generated to bacterially expressed human proen- 
kephalin fusion polypeptides (Spruce  et al.,  1988,  1990), 
we  have  localized  proenkephalin  within  the  nucleus  of 
Swiss  3T3  cells  by immunofluorescence microscopy and 
immunoblotting. Nuclear immunofluorescent staining pro- 
cedures were performed on paraformaldehyde fixed cells. 
Fig. 1, A-D, illustrates confocal micrographs of the three 
Figure 1.  Subnuclear distribution of proenkephalin.  Indirect  immunofluorescent staining was carried  out on exponential  cultures of 
Swiss 3T3 cells. All microscopy was performed with a  confocal laser scanning microscope. (A-D) Representative examples of nuclear 
proenkephalin distributions revealed with different PE mAbs  (A and B, PE-1  and PE-2, fine punctate;  C, PE-15, coarse punctate; D, 
PE-16, speckled). (E and F) The change in proenkephalin distributions after actinomycin treatment (E, PE-15; F, PE-16).  Bars, 25 ixm. 
(G and H) Zoom images of a nucleus colabeled with PE-16 (G) and 3C5 (H), an antibody that detects interchromatin granules. 
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cleus, using indirect immunofluorescent detection. Each of 
the 15 PE mAbs gives one of these staining patterns which 
we describe as fine punctate (A  and B), coarse punctate 
(C), and speckled (D). (The coarse punctate and speckled 
staining  patterns  are  also  observed  in  cells  fixed  with 
methanol  and  acetone.)  In  asynchronous,  exponentially 
growing cells, the coarse punctate and speckled (C and D) 
patterns are visible in all interphase nuclei. The fine punc- 
tate pattern (A and B) is usually visible in very few inter- 
phase  cells  (<5%)  except under certain growth circum- 
stances (as discussed later). 
After treatment of the cells with 10 ~g/ml actinomycin 
for 5 h (Fig. 1, E and F), in most cases the subnuclear orga- 
nization was lost and replaced by a bright, diffuse distribu- 
tion. Fig. 1 E illustrates the change in the coarse punctate 
and Fig. 1 F the change in the speckled pattern, which now 
become  indistinguishable.  Actinomycin,  an  inhibitor  of 
transcription,  is  also  known  to  have  effects on  nuclear 
architecture (Nickerson and Penman,  1992)  . Therefore, 
disruption of proenkephalin organization could reflect lib- 
eration  of proenkephalin  from nuclear  substructures  or 
complexes, to become diffusely liberated in  the  nucleo- 
plasm. 
To determine if any of the proenkephalin localization 
patterns  correspond to  identifiable nuclear  subcompart- 
ments, double-label immunofluorescent staining was car- 
ried out with other antinuclear antibodies. The speckled 
pattern (Fig. 1, D  and G) was found to colocalize with in- 
terchromatin granules (Fig. 1 H), detected with the anti- 
body 3C5  (a gift from Bryan Turner, University of Bir- 
mingham, Birmingham, U.K.; Turner and Franchi, 1987). 
Fig. 1, G and H, shows images at higher magnification of a 
nucleus dual labeled with PE-16 (G) and 3C5 (H), an IgM 
mAb,  followed with  subclass-specific second  antibodies. 
Neither pattern  was  observed with  the  incorrect second 
antibody,  which  excludes cross-reactivity.  Colocalization 
was confirmed by computer overlay of the confocal images 
(not shown).  Interchromatin granules represent a  defin- 
able nuclear substructure, detectable by electron micros- 
copy (Wassef, 1979).  Proteins involved in RNA process- 
ing, including small nuclear ribonucleoproteins (snRNPs) 
and the splicing factor SC-35 (Spector et al.,  1991),  have 
also been localized to this compartment, but the  exact 
nature of the events that occur here is unresolved. Indeed, 
proteins not involved in splicing, such as glutathione 
S-transferase, have an identical distribution (Bennett and 
Yeoman,  1985),  so the  compartment appears multifunc- 
tional.  The coarse punctate  (Fig.  1  C)  pattern  does not 
colocalize with 3C5 staining, which indicates that this dis- 
tribution  is  distinct  from  interchromatin  granules.  We 
have failed to detect proenkephalin in coiled bodies (by 
costaining  with  anti-coilin  antibodies  from  A.  Lamond, 
European  Molecular  Biology  Laboratory,  Heidelberg, 
Germany),  which  is  another  domain  implicated  in  the 
RNA processing pathway (Carmo-Fonseca et al., 1992). 
Restricted Revelation of Proenkephalin Epitopes 
We observed one of three predominant staining patterns 
with each monoclonal antibody. The speckled and coarse 
punctate patterns, seen in the majority of proliferating in- 
terphase  cells,  appear  not  to  overlap,  because  only the 
speckled pattern colocalizes with interchromatin granules. 
In a proliferating cell population, the fine punctate pattern 
characteristic of several antibodies is seen in <5 % of cells. 
This indicates that, at least in proliferating cells, only lim- 
ited regions of the proenkephalin molecule may be acces- 
sible to antibodies. To test this, we needed more informa- 
tion about the binding domains of the PE mAbs. 
Proenkephalin epitopes recognized by these antibodies 
have now been fully characterized with phage display li- 
braries incorporating randomly generated sequences and 
with synthetic peptides (B6ttger et al., 1995).  Fig. 2 sum- 
marizes this information and shows the core sequences of 
the epitopes recognized by the proenkephalin mAbs within 
the  primary  sequence  of  human  proenkephalin.  Addi- 
tional data (B6ttger et al., 1995) that define differences in 
antibody fine specificities indicate that  the  higher order 
structure of the protein may influence epitope recognition. 
The antibodies PE-1, 13, 20, 21, 22, and 24 all reveal a 
fine punctate staining pattern (Fig. 1, A and B). These an- 
tibodies recognize the domains II and III (Fig. 2), which 
are adjacent on the proenkephalin molecule. Because the 
antibody PE-2, directed to a different site on proenkepha- 
lin (Fig. 2, domain IV), also reveals the same pattern, it is 
very likely that  this  is  an  authentic  reflection of proen- 
kephalin distribution. The revelation of domain I  (recog- 
nized by PE-14, etc.) in this distribution remains possible 
because it may overlap with the speckled pattern. The fine 
punctate pattern of staining is normally evident in a very 
small percentage of proliferating, interphase cells (>5%) 
but is transiently revealed in response to external growth 
arrest and differentiation signals  in up to  100%  of cells 
(see later section). 
A rather more complex picture emerges when analyzing 
the epitopes revealed in the coarse punctate and speckled 
distributions. The antibodies PE-14, 16, 17, 18, 19, and 25 
are all associated with a speckled staining pattern (Fig. 1 
MARFLTLCTW LLLLGPGLLA TVRAECSQDC  ATCSYRLVRP  ADINFLACVM  50 
ECEGKLPSLK  IWETCKELLQ LSKPELPQDG  TSTLRENSKP  EESHLLA~  i00 
GGFmYGGF  MKKMDELYPM EPEEEANGSE  ILAKRYGGFM KKDAEEDDSL  150 
IV 
ANSSDLLKELLETGDNRERS  HHQD~YC-GFMRGLKRSPQLE  200 
I  II  III 
DEAKELQKRY  GGFMRRVGRP  EWWMDYQKRY  GGFLKRFAEA  LPSDEEGESY  250 
SKEVPEMEKR  YGGFMRF  267 
I  PE-14,  PE-15,  PE-16,  PE-17,  PE-18,  PE-19,  PE-23,  PE-25 
II  PE-13,  PE-20,  PE-21,  PE-22,  PE-24 
III  PE-I 
IV  PE-2 
Figure 2.  Location of epitopes recognized by anti-proenkephalin 
mAbs within the primary sequence of proenkephalin.  Epitopes 
were defined using phage display libraries and synthetic peptides. 
Four antigenic domains have been identified (I to IV); antibodies 
that recognize these domains are listed in the lower panel. 
The Journal of Cell Biology, Volume 130, 1995  1254 D) and all recognize the same epitope (Fig.  2, domain I). 
An exception is the antibody PE-15, which recognizes do- 
main I but which gives a coarse punctate (Fig. 1 C) rather 
than a speckled pattern. Nevertheless, a comparison of the 
phage insert sequences (containing 6, 12, or 24 amino ac- 
ids;  BOttger et  al.,  1995)  recognized by these  antibodies 
shows that  alteration  of sequences  that  flank  the  DLL- 
KELL core epitope  differentially constrains epitope rec- 
ognition by PE-14 and  PE-15,  a  situation  that  could be 
simulated in the nucleus by differences in the conforma- 
tion or intermolecular interactions of proenkephalin in the 
two distributions.  In addition, we have been able to pro- 
vide additional evidence for the authenticity of these stain- 
ing patterns with a  differential extraction procedure (see 
later). 
Intact Proenkephalin Precursor Protein Resides within 
the Nucleus 
To confirm the existence of proenkephalin protein within 
the nucleus of 3T3 cells,  nuclear isolates were made from 
cells  in exponential growth phase by gentle homogeniza- 
tion in a  nuclear isolation buffer followed by centrifuga- 
tion through a sucrose cushion. Isolated nuclei were then 
immunoblotted against all 15 PE mAbs individually  (Fig. 3 a, 
lanes 1 to 16; lane 15 no antibody control). A  strong dou- 
blet or triplet of bands with apparent molecular weights of 
34.5, 33, and 31.5 is detected with several of the antibodies, 
including antibodies directed to different epitopes, such as 
lanes 3, 4, and 11 (PE-13, 14, and 21). The reason some of 
Figure 3.  Confirmation of the existence of proenkephalin protein 
and mRNA in 3T3 cells. (a) Nuclei were isolated from proliferat- 
ing 3T3 cells, then  lysed and  loaded  onto a preparative  SDS- 
polyacrylamide  gel. After electroblotting,  strips of membrane 
were incubated with individual PE mAbs, followed by peroxidase 
conjugated anti-mouse  IgG before a chemiluminescence reaction 
(lanes 1-14: PE-1, 2, 13 through 24, respectively; lane 15, no pri- 
mary antibody control; lane 16, PE-25; M, molecular mass marker 
track in kilodaltons). (b) Separate immunoblot analysis: lanes A-C 
compare  transfected  proenkephalin  in PC12 cells (lane B) with 
proenkephalin  in nuclear isolates (A) and total  cell lysates (C) 
from 3T3 cells. Lanes A-C were immunostained with the same 
PE mAb.  (c) Lane 2 shows PCR product  obtained  with mouse 
proenkephalin  specific primers from 3T3 cell reverse transcripts; 
lane 1, nonmurine cell control; lane M, DNA size markers. 
the antibodies work better in immunofluorescence than in 
immunoblotting may be  because  of a  difference  in  the 
folding of nuclear proenkephalin on a blot compared with 
that in situ.  In a separate immunoblot comparison (Fig. 3 
b),  3T3  cell  proenkephalin  in  nuclear  isolates  (lane  A) 
comigrates with that in total cell lysates (C) and with hu- 
man proenkephalin overexpressed in PC12 cells  (lane B; 
Spruce et al., 1990). The observed molecular weight of nu- 
clear  proenkephalin  is  consistent with  its  existence  in  a 
predominantly uncleaved state (Spruce et al., 1988, 1990). 
Proenkephalin mRNA Exists in 3T3 Cells 
Proenkephalin mRNA has previously been demonstrated 
in transformed Fr3T3 cells (Matrisian et al., 1988). In non- 
transformed Swiss 3T3 cells, we observe a low abundance 
proenkephalin  transcript  on Northern blot  analysis  (not 
shown). To definitively show the existence of proenkephalin 
mRNA in 3T3 cells,  we carried out PCR amplification of 
reverse transcripts synthesized from 3T3 cell mRNA. Pri- 
mers specific to mouse proenkephalin were used: 5'-CTT- 
CITFCAAAATCTGGGAGACCT-3' and  5'-ATACCT- 
CTTGCTCATGTCTTCGTC-3'. A single PCR product of 
392 base pairs was isolated (Fig. 3, c, lane 2) which was se- 
quenced using the ds DNA cycle sequencing system (Be- 
thesda Research Laboratories Life Technologies Inc., Gaith- 
ersburg,  MD),  incorporating both PCR primers  in cycle 
sequencing reactions.  The sequence of the PCR product 
was identical to that segment of the mouse proenkephalin 
sequence flanked by the two primers. 
Subnuclear Fractionation Confirms Differential 
Compartmentalization of Nuclear Proenkephalin 
To validate  our  data  further,  we  carried  out subnuclear 
fractionation to determine if extraction of proenkephalin 
from particular distributions can be correlated with libera- 
tion of proenkephalin into the extraction supernatant. Pel- 
leted cells and cells on tissue culture slides  were extracted; 
supernatants from the former were subjected to nonradio- 
active immunoprecipitation with PE mAbs (Fig.  4 b) and 
compared with  cells  on  slides  fixed  and  immunostained 
postextraction  (Fig.  4 a).  Upper panels show nuclei with 
speckled  (PE-16)  staining  (A)  after  preextraction  with 
CSK buffer (see  Methods),  (B)  after 0.25  M  ammonium 
sulfate treatment (AMS),  1 and (C) after a combination of 
DNAse and RNAse treatment. The speckled pattern is re- 
sistant to CSK preextraction (A) and nuclease treatment 
(C) but is sensitive to salt (B). The disappearance of this 
pattern coincides with the appearance of immunoprecipi- 
table  proenkephalin in  the supernatant  after salt  extrac- 
tion (Fig.  4 b, AMS lane c).  A  product that resolves as a 
doublet migrating at approximately 34 and 31 kd is precip- 
itated with PE-16 (AMS lane c). A different PE mAb was 
used to probe the blotted immunoprecipitation products. 
No products are precipitated from supernatant after CSK 
treatment  (Fig.  4  b,  CSK lane  c),  with  control antibody 
(Fig.  4 b,  AMS lane a,  anti-p53  ascites)  or without anti- 
body (Fig. 4 b, AMS lane b, no ascites). 
1. Abbreviations used in this paper: AMS, ammonium sulfate treatment; 
PCNA, proliferating cell nuclear antigen. 
B6ttger and Spruce Nuclear Localization of Proenkephalin  1255 Figure 4.  Proenkephalin  exists in  biochemically distinct subnuclear  compartments.  (a)  Proenkephalin  immunofluorescence staining 
(upper row, speckled pattern, PE-16; lower row, coarse punctate pattern, PE-15) was carried out on 3T3 cells after CSK preextraction 
(A and D), after salt (0.25  M  ammonium sulfate, AMS, B  and E), or after nuclease extraction (DNAse followed by RNAse, C and F). 
Bars, 25  Ixm. (b)  In parallel with immunolocalization after extraction, harvested 3T3 cells were sequentially extracted with CSK, salt 
(AMS), and DNAse then RNAse; after each extraction, soluble and insoluble fractions were separated by centrifugation and postex- 
traction supernatants and then immunoprecipitated with PE mAbs or with control antibody. Immunoprecipitation products were immu- 
noblotted against a PE mAb followed by an anti-mouse second antibody and then detected using ECL. H  and L denote heavy and light 
chain immunoglobulin bands deriving from the precipitating antibody. In all cases, precipitating antibodies were as follows: lane a, anti- 
p53; lane b, no precipitating antibody; lane c, PE-16; and lane d, PE-15. (c) Cell pellets corresponding to postextraction supernatants in 
Fig. 4 b were analyzed by immunoblot to assess the proportion of proenkephalin remaining in the insoluble fraction after each extrac- 
tion. Lane d, untreated pellet; lane c, pellet after CSK preextraction; lane b, pellet after salt extraction; and lane a, pellet after salt and 
nuclease extraction. 
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punctate  (PE-15)  staining  pattern  (D)  after  CSK  treat- 
ment, (E, binucleate cell) after AMS, and (F) after com- 
bined DNAse  and  RNAse  treatment.  This immunofluo- 
rescent staining pattern is resistant to CSK preextraction 
(D) and to salt extraction (E) but is sensitive to nuclease 
treatment (F). Sequential treatment of pelleted cells with 
AMS, then DNAse and RNAse, is associated with the ap- 
pearance of PE-16-immunoprecipitable proenkephalin in 
the extraction supernatant, visible as a weak doublet of the 
same molecular size as that extracted by salt alone (Fig. 4 
b, RNAse lane c). PE-15, which recognizes the same core 
epitope as PE-16, fails to immunoprecipitate proenkepha- 
lin  from  any  extraction  supernatants  (Fig.  4  b,  lanes  d 
throughout),  which could be explained by recognition of 
different conformational forms of proenkephalin by PE- 
16 and PE-15 because of differential constraints on revela- 
tion of the core epitope. When subjected to nuclease treat- 
ments in the reverse order or to RNAse alone, the coarse 
punctate  proenkephalin  staining  is  only partially  dimin- 
ished; DNAse when free of RNAse has no effect. We at- 
tribute this to a cooperative effect of DNAse, perhaps im- 
proving accessibility for RNAse extraction. 
To assess the proportion of proenkephalin remaining in 
the  insoluble  fraction  following  extraction,  cell  pellets 
were immunoblotted against PE mAb (Fig. 4 c). Lanes d 
(untreated)  and  c  (CSK treated)  show  a  prominent PE- 
immunoreactive band that disappears after sequential salt 
(lane b) and nuclease (lane a) extraction. Although proen- 
kephalin in the cell pellet after salt extraction and before 
nuclease extraction is below the limit of detection by im- 
munoblot  analysis, a  small  quantity  of proenkephalin  is 
liberated into the supernatant after sequential salt and nu- 
clease extraction; this is consistent with the persistence of 
the coarse punctate staining pattern after salt extraction. 
From these data we conclude that the majority of nuclear 
proenkephalin resides in a salt-extractable compartment; a 
smaller proportion is in  a  nuclease-extractable  compart- 
ment, which corresponds to the coarse punctate distribu- 
tion that varies in intensity between cells. 
We  have  not  yet  examined  the  behavior  of the  fine 
punctate  staining  pattern  under  these  extraction  condi- 
tions because it is usually visible in only a very small per- 
centage  of cells  except under  special circumstances  (see 
later  section).  However,  the  pattern  is  diminished  and 
sometimes  abolished  when  cells  have been subjected  to 
methanol. This provides evidence for a further difference 
in the association of proenkephalin with the nuclear subar- 
chitecture when proenkephalin is in this distribution, since 
it contrasts with the stability of the speckled and coarse 
punctate staining distributions when cells are subjected to 
methanol alone or in combination with acetone (not shown). 
Change in the Revelation of Proenkephalin Antigenic 
Domains in the Transition to Growth Arrest 
Fibroblasts exit the cell cycle, becoming diverted to a qui- 
escent or GO state, when deprived of serum or growth fac- 
tors, or when maintained at confluency to induce contact 
inhibition.  We examined the behavior of nuclear proen- 
kephalin in both of these states of growth arrest. 
When 3T3 cells are serum deprived, there is variation in 
the  subnuclear  response  of  proenkephalin.  In  general, 
when cells are serum deprived at high but not low density, 
there is a reduction in nuclear proenkephalin immunofluo- 
rescence. Serum deprivation, particularly when in combi- 
nation with high density culture conditions, increases the 
tendency of 3T3 cells to spontaneously transform. There- 
fore, to exclude these effects, we chose to examine MRC-5 
human  embryonic lung  fibroblasts which  are  known  to 
quiesce  more reliably in response to  serum  deprivation. 
An asynchronous population of MRC-5 cells will exit into 
GO N18-22 h  after serum withdrawal,  the time taken to 
traverse the cell cycle. 
We  examined  proenkephalin  immunofluorescence  in 
MRC-5  cells  at  various  times  after transfer from  10  to 
0.2% FCS, illustrated in Fig. 5. Cells were immunostained 
at intervals with anti-proenkephalin mAbs and with anti- 
bodies to proliferating cell nuclear antigen (PCNA)  (pro- 
vided by N. Waseem and D. Lane, University of Dundee, 
Dundee, U.K.; Waseem and Lane, 1990), to confirm their 
exit from the cell cycle. PCNA,  an accessory protein for 
DNA polymerase delta,  is localized to DNA replication 
complexes in S phase of the cell cycle. This is revealed by a 
punctate distribution of the protein; after liberation from 
replication  complexes, PCNA  becomes diffusely distrib- 
uted  in  the  nucleoplasm  (Bravo  and  Macdonald-Bravo, 
1987). Because PCNA has a long half-life within the nu- 
cleus, only the punctate staining pattern is a reliable indi- 
cator of cell proliferation. 
Fig. 5, column A, shows proenkephalin immunostaining 
before serum withdrawal;  column B, cells 4  to 6  h  after 
transfer to 0.2% FCS; C, cells after 24 h of serum depriva- 
tion. As in 3T3 cells, the speckled stain (A, upper row, de- 
tected with PE-18)  is seen in all interphase  nuclei  in  an 
asynchronous cell population. The fine punctate stain (A, 
second  row,  PE-2)  is  rarely present  in  an  exponentially 
growing  population,  again  as  in  3T3  cells.  The  coarse 
punctate pattern, detected with PE-15 in 3T3 cells, is not 
seen. This may reflect either interspecies variation in sub- 
nuclear compartments or a difference in the growth and/or 
differentiation state of these two fibroblast cell lines. 
4 to 6 h  after serum withdrawal (Fig. 5, column B), the 
speckled stain is unchanged from baseline. However, there 
is a  dramatic change in the fine punctate  stain, detected 
with antibodies directed to domains II, III, and IV. Barely 
visible at baseline, it is now present in up to 100% of cells 
(Fig. 5, column B, middle row). At this stage, the cells are 
still traversing the cell cycle; S-phase cells with punctate 
PCNA  stain  (B,  lower  row)  are  present,  together  with 
mitotic cells (a metaphase cell is seen in B, detected with 
PE-18; proenkephalin immunostaining changes at mitosis, 
becoming bright and diffuse, and is excluded from the con- 
densed  chromosomes,  seen  in  this  cell  aligned  on  the 
metaphase  plate).  The  revelation  of proenkephalin  epi- 
topes in a fine punctate distribution is no longer seen be- 
yond 8 h. 
24 h after serum withdrawal (Fig. 5, column C), the cells 
have exited the cell cycle; punctate PCNA staining is ab- 
sent, and no mitotic cells are seen. At this stage, the speck- 
led nuclear stain appears unchanged (upper row) and the 
fine punctate stain remains absent (middle row). 
The prompt unmasking of proenkephalin antigenic do- 
mains  II, III, and  IV upon  mitogenic factor withdrawal 
may reflect receipt of a growth arrest signal from the ex- 
tracellular environment. To test whether this phenomenon 
B6ttger and Spruce  Nuclear Localization of Proenkephalin  1257 Figure 5.  Mitogen withdrawal induces an early and transient response in nuclear proenkephalin. MRC-5 cells were seeded sparsely in 
10% FCS, then transferred to 0.2% FCS after 24 h. Cells were fixed and immunostained with PE or PCNA mAbs (A) before and (B and 
C) at intervals after serum withdrawal. Column B represents cells 4 to 6 h after serum withdrawal, before cell cycle exit. Bars, 10 txm (A, 
lower two panels) or 25 ~m (remaining panels). 
was also present  after another stimulus  to growth arrest, 
we examined 3T3 cells  rendered contact inhibited by cul- 
ture at high density in the presence of 10%  FCS. At N2 d 
after plating, when cells  have reached confluence but are 
not yet arrested, revelation of proenkephalin antigenic do- 
mains II, III, and IV in a fine punctate distribution is again 
seen in the vast majority of cells, and again the response is 
transient (not shown). If 3T3 cells  are maintained at high 
density, there is down-regulation of nuclear proenkephalin 
staining. 
The changes in nuclear proenkephalin immunofluores- 
cent staining patterns in the transition to growth arrest oc- 
cur in the absence of any detectable change in the amount 
or  molecular forms  of proenkephalin  protein  compared 
with that extracted from nuclei of proliferating cells  (Fig. 
3).  Thus, the changes in staining must reflect differential 
unmasking  and  concealment of proenkephalin  epitopes, 
possibly combined with subnuclear redistribution,  during 
the induction of growth arrest. 
Dynamic Subnuclear Reorganization of  Proenkephalin 
in Myoblasts Undergoing Differentiation 
In undifferentiated rodent myoblasts (C2C12 cells;  Yaffe 
and Saxel,  1977, subcloned by H. Blau), proenkephalin ex- 
ists  in the nucleus in coarse punctate  (Fig.  6, upper row, 
D1) and speckled distributions  (not shown), as in embry- 
onic fibroblasts. Again, the fine punctate pattern revealed 
with antibodies directed to domains II, III, and IV is seen 
very rarely  in  undifferentiated  cells  (Fig.  6,  lower  row, 
D1).  However, if C2C12 cells  are  induced to commence 
differentiation either by growth to confluence or by trans- 
fer from FCS to 1%  donor horse serum, domains II, III, 
and IV in a  fine punctate distribution  are transiently re- 
vealed in up to 100%  of cells  (Fig.  6, D4).  At this stage 
(between days 3 and 5) the cells have not yet fused to form 
myotubes, and they are proliferating asynchronously. As 
in fibroblasts in transition to growth arrest, the revelation 
of multiple proenkephalin epitopes in myoblasts early in 
their differentiation program is also transient  (Fig.  6, D7 
shows an absence of PE-2 staining). However, domains II, 
III, and IV are revealed again at a later stage of differenti- 
ation (Fig.  6, DIO, lower row) when the cells are fusing to 
form  multinucleated  myotubes.  In  multinucleate  myo- 
tubes, the revelation of domain I in a punctate distribution 
changes to become brighter and more diffuse (Fig. 6, DIO, 
upper  row).  Throughout  these  stages,  levels  of  proen- 
kephalin protein detected by immunoblotting remain ap- 
The Journal of Cell Biology, Volume 130, 1995  1258 Figure 6.  Change in nuclear proenkephalin staining during myoblast differentiation. C2C12 cells were transferred from FCS-containing 
medium to medium with 1% donor horse serum. Cells were fixed and immunostained with PE mAbs at intervals (days 1, 4, 7, and 10) 
during differentiation. On day 4 (D4), multiple proenkephalin epitopes are transiently revealed in up to 100% of cells. 
parently unchanged. Thus, as in fibroblasts in transition to 
growth arrest,  there  is  dynamic unmasking and  conceal- 
ment of proenkephalin epitopes, and possibly subnuclear 
redistribution, as myoblast differentiation proceeds. 
Proenkephalin Devoid of a Signal Peptide 
Sequence Is Targeted to the Nucleus in Transiently 
Transfected COS Cells 
with the first ATG codon were changed and then trans- 
fected separately into COS cells.  In all  cases, translation 
remained  efficient,  and  a  proportion  of the  transfected 
gene product was translocated to the nucleus; that is, the 
result  was  indistinguishable  from  mutation  of  the  first 
ATG alone (Fig. 7, second row). This indicates that proen- 
kephalin can be translated from one or more downstream 
initiation codons. 
Additional  ATG  codons within  proenkephalin  repre-  To determine  which regions of the proenkephalin mole-  ..........  -- 
senting potential sites of alternative initiation are located  cule may be involved in nuclear targeting, we have begun a 
series  of  mutagenesis  experiments.  In  COS  cells  tran- 
siently transfected with nonmutated proenkephalin cDNA, 
the transfected gene product is localized exclusively in the 
cytoplasm (Fig.  7, top  row).  Immunofluorescent staining 
was performed with antibodies to two different epitopes 
(domains II or III, and domain I) to confirm its authentic- 
ity.  In  contrast,  if  site-directed  mutagenesis  is  used  to 
change  the  normal  ATG  initiation  codon  to  an  ATC 
codon from which translation cannot be initiated, efficient 
expression  of the  transfected  gene  is  seen  but  the  gene 
product is now targeted to the nucleus as well as to the cy- 
toplasm (Fig.  7, second row). From this we conclude that, 
in the absence of the normal AUG initiation codon, trans- 
lation can be initiated at another codon to produce a form 
of proenkephalin with nuclear and cytoplasmic fates. 
It is known that FGF molecules can be translated from 
upstream CUG initiation codons; this leads to the produc- 
tion  of forms  of FGF  with  both  nuclear  and  secretory 
pathway destinies (B0gler et al.,  1991; Kiefer et al., 1994). 
The  proenkephalin  gene  possesses  two  upstream  CTG 
codons, which are in translational reading frame with the 
coding sequence. To test  if translation could be initiated 
from one or both of these CTG codons, mutant cDNAs 
were  generated  in  which  one  or  the  other  of the  CTG 
codons, both CTG codons, or both CTG codons together 
downstream from the signal peptide sequence. This sug- 
gested to us that absence of the signal peptide sequence 
may cause the molecule to circumvent the secretory path- 
way and thereby permit nuclear transfer. To test this we 
used a PCR approach to delete the signal sequence but re- 
tain  the  normal  ATG initiation  codon.  The  product  of 
such  a  construct is  also  targeted  to  the  nucleus  (Fig.  7, 
third row, ATGAsig). This indicates that removal of the 
signal  peptide  is  sufficient  to  confer  a  nuclear  fate  to 
proenkephalin. 
Discussion 
Subnuclear Revelation of Proenkephalin Depends on 
Growth Arrest and Differentiation Signals 
In this paper we show that proenkephalin is a nuclear pro- 
tein in fibroblast and myoblast cell lines and that the reve- 
lation of antigenic domains is dependent on signals from 
the extracellular growth environment. 
In  nuclei  of  proliferating  interphase  Swiss  3T3  and 
MRC-5  cells,  and  in  undifferentiated  C2C12  myoblast 
cells, the exposure of antigenic domains on proenkephalin 
is restricted. This may be a result of either conformational 
constraints or complex formation with other nuclear pro- 
teins, which may regulate the exposure or interactions of 
B6ttger and Spruce Nuclear Localization of  Proenkephalin  1259 functional domains. It may also serve to prevent enzymatic 
cleavage  of proenkephalin,  a  molecule  ordinarily  highly 
susceptible to proteolytic breakdown. 
We  observed  low  levels  of  proenkephalin  mRNA  in 
nontransformed 3T3 cells. Higher levels of proenkephalin 
mRNA have previously been described  to exist in trans- 
formed 3T3 cells (Matrisian et al., 1988). We have prelimi- 
nary data that proenkephalin may relocate to the cytoplasm 
when 3T3 cells undergo spontaneous transformation, which 
could explain the higher mRNA levels if this is associated 
with  a  shorter  protein  half-life.  However,  the  apparent 
revelation of cytoplasmic proenkephalin,  such as after salt 
extraction  (Fig. 4 a, panels B  and E)  and in MRC-5 cells 
(Fig.  5),  suggests  that  proenkephalin  exists  in  the  cyto- 
plasm as well as in the nucleus of nontransformed cells but 
that it is more often masked in the cytoplasm of nontrans- 
formed cells. 
In the transition to growth arrest,  antigenic domains on 
Figure  Z  Nuclear  targeting 
of  mutated  proenkephalin 
transiently  transfected  into 
COS cells.  Nonmutated  and 
mutated proenkephalin cDNAs 
were  transiently  transfected 
into COS cells; cellular local- 
ization of transfected proen- 
kephalin  was  confirmed  by 
indirect  immunofluorescence 
staining  with  PE  mAbs  to 
different epitopes (domain H 
or III, left-hand column; do- 
main  L  right-hand  column). 
The  upper  row  shows  the 
product of nonmutated proen- 
kephalin (ATG);  the second 
row, proenkephalin  mutated 
at  the  first  ATG  codon 
(ATC); the third row, proen- 
kephalin mutated to remove 
the  signal  peptide  sequence 
(ATGAsig); and  the  bottom 
row, control cells transfected 
with  13-galactosidase  expres- 
sion  vector  alone  ([3-gal). 
Bars, 25 p~m (third row) and 
10 p~m (remaining rows). 
nuclear proenkephalin  are transiently  unmasked  in up to 
100%  of cells;  this  coincides with  newly established  cell- 
cell contact in 3T3 cells and occurs within 4 to 6 h of mito- 
gen  withdrawal  in  MRC-5  cells.  The  rapidity  of the  re- 
sponse, together with the existence of S-phase and mitotic 
ceils at this time, is therefore inconsistent with synchroni- 
zation  at  a  G1/G0  boundary.  The  same  phenomenon  is 
also  observed  in  rodent  myoblast  (C2C12)  cells  early in 
their differentiation  program. Together,  these  data imply 
that  nuclear proenkephalin  can acknowledge  signals  that 
mediate  growth  arrest  and  differentiation  in  a  time  win- 
dow apparently independent of cell cycle stage. 
Mechanism of Nuclear Targeting 
We have shown that removal of the signal peptide is suffi- 
cient  to  confer  a  nuclear  fate  to  transiently  transfected 
proenkephalin in COS ceils. The similarity of the molecu- 
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from which the signal peptide will have been cleaved dur- 
ing translocation across the endoplasmic reticulum mem- 
brane  while  translation  is  still  proceeding,  is  consistent 
with derivation of the nuclear form from a primary trans- 
lation product that has never possessed a signal sequence. 
How might a primary translation product that lacks a sig- 
nal sequence arise in vivo? It is known that a population of 
cells in the rat forebrain contains proenkephalin primary 
transcripts initiated from an alternate site in intron A  and 
lacks exon 2-containing transcripts (Brooks et al., 1993). A 
rat proenkephalin transcript that lacks exon 2 (equivalent 
to exon 3 in the human gene) would direct a protein de- 
void of a signal sequence. It is possible, therefore, that al- 
ternate  transcription  initiation,  alternate  splicing,  or  a 
combination of both could lead to a  primary translation 
product devoid of a signal peptide, which may then be ca- 
pable of nuclear translocation. 
We still, however, cannot definitively exclude the addi- 
tional possibility that translation initiation from one of the 
upstream  in-frame  CUG  codons  in  proenkephalin  may 
also  occur,  as with FGF family members (Biagler et  al., 
1991;  Kiefer et  al.,  1994).  Furthermore,  it is well  estab- 
lished that secreted growth factors internalized by target 
cells can be translocated to the interior of the nucleus as 
well as to the nuclear membrane (Yankner and Shooter, 
1979;  Johnson  et  al.,  1980;  Rakowicz-Szulczynska et  al., 
1986).  Nuclear translocation of occupied polypeptide hor- 
mone  (insulin)  cell  surface  receptors  has  also  been  de- 
scribed (Podlecki et al., 1987). It therefore remains possi- 
ble that  re-uptake  of a  secreted form of proenkephalin, 
possibly remaining bound to cell surface receptors, may be 
an additional mechanism of nuclear transfer; however, nu- 
clear targeting of proenkephalin  mutated to remove the 
signal sequence, which therefore cannot gain access to the 
secretory pathway, demonstrates that "intracrine" nuclear 
transfer can occur. 
Why Should a Neuropeptide Precursor Have Such 
Diverse Roles? 
We have shown that proenkephalin exists as a nuclear pro- 
tein integrated with pathways that mediate growth arrest 
and  differentiation  signals.  In  the  nervous  system,  en- 
kephalin peptides act as neurotransmitters and neuromod- 
ulators. Other proteins, most notably the crystallins, have 
functionally diverse roles subserved by common protein 
domains  (Wistow et al.,  1987),  which  may reflect evolu- 
tionary molecular economization ("gene sharing"). A  the- 
oretical paper has indicated the possibility that the opioid 
precursors  prodynorphin  and  proenkephalin  may  be 
DNA-binding proteins on the basis of their possession of 
zinc  finger  and  helix-loop-helix  domains,  together  with 
amino acid homology with hunchback,  lyl-1, and related 
proteins (Bakalkin et al., 1991). This molecular possibility 
will be interesting to explore. 
A  negative consequence  of gene sharing is that it may 
impose  an  unfavorable  evolutionary  constraint  in  that 
adaptive change in one function should not be detrimental 
to the  other(s).  However,  obligate  coupling  of adaptive 
change in the two or more functions may be advantageous 
if a  common signaling  or  effector pathway  immediately 
downstream of the multifunctional protein is involved. It is 
possible that the diverse roles of proenkephalin are a re- 
sult of coevolution with common signaling mechanisms to 
subserve different functions according to subcellular loca- 
tion or cell type. Phosphoinositol hydrolysis occurs within 
the nucleus of Swiss 3T3 cells (Divecha et al., 1991).  This 
opens up the possibility that receptor-coupled signals gen- 
erated either within the nucleus or at the nucleocytoplas- 
mic interface could be transduced in a similar way to sig- 
nals at the cell surface. Opioid binding in association with 
a  nuclear  fraction from developing cerebellum has been 
reported (Zagon et al., 1991). Belcheva et al. (1993) have 
shown the existence of G protein-coupled delta opioid re- 
ceptors  in  highly  purified  nuclear  membrane  fractions 
from a  neurohybrid  cell  line;  uncoupled  opioid  binding 
sites that may be chromatin-associated have also been de- 
tected. We have shown that an opioid precursor, proen- 
kephalin, exists in the nucleus in an apparently unprocessed 
form in that we fail to detect proteolytic intermediates with 
our PE mAbs (Spruce et al., 1988).  It remains possible that 
proenkephalin may undergo localized proteolytic cleavage 
to generate  opioid ligands  at specific subnuclear  sites of 
activity, or proenkephalin could be acting independently 
of opioid receptors. Opiate binding at the cell surface has 
also been linked to proliferation and differentiation events 
(Hauser et al., 1989,  1992). Taken together, these results 
suggest that proenkephalin and opioid peptides could be 
involved in growth control in the nucleus and at the cell 
surface. There is evidence that nonopioid neuropeptides 
also have roles in cell proliferation  (Nilsson et al.,  1985; 
Haegerstrand et al., 1990), indicating that there may have 
been  evolutionary  pressure  to  coordinate  neuropeptide 
function with growth control. 
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